Literature DB >> 6226225

Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis.

G W Hunninghake, G N Bedell, D C Zavala, M Monick, M Brady.   

Abstract

Using a human T-cell line sensitive to interleukin-2 (IL-2), we evaluated supernatants of unstimulated, purified lung T-lymphocytes from patients with sarcoidosis and high-intensity alveolitis (active disease), patients with sarcoidosis and low-intensity alveolitis (inactive disease), patients with idiopathic pulmonary fibrosis, and normal volunteers for the presence of IL-2. After 24 h in culture, supernatants of lung T-cells from patients with sarcoidosis and high-intensity alveolitis contained significantly greater amounts of IL-2 than did supernatants of lung T-cells from the other 3 groups, which we used as controls (p less than 0.001 for each comparison). The IL-2 present in supernatants of lung T-cells had a molecular weight of approximately 15,000 daltons and the supernatants that contained IL-2 significantly (p less than 0.01) increased in vitro immunoglobulin production by T-cell-depleted normal mononuclear cell suspensions stimulated with pokeweed mitogen. These studies suggest that the release of IL-2 by lung T-cells may explain in part the local proliferation of T-cells and hypergammaglobulinemia that are characteristic of pulmonary sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226225     DOI: 10.1164/arrd.1983.128.4.634

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  31 in total

1.  Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells.

Authors:  A Prasse; C G Georges; H Biller; H Hamm; H Matthys; W Luttmann; J C Virchow
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis.

Authors:  B Balbi; D R Moller; M Kirby; K J Holroyd; R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

3.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin-2 production in Schistosoma mansoni infection.

Authors:  R C Mathew; D L Boros
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

5.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

6.  Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis.

Authors:  V De Rose; L Trentin; M T Crivellari; A Cipriani; G Gialdroni Grassi; E Pozzi; G Folco; G Semenzato
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

Review 7.  Immune aspects of sarcoidosis.

Authors:  L W Poulter
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

8.  Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3.

Authors:  A O Fels; C F Nathan; Z A Cohn
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 9.  Cells and molecules involved in the development of sarcoid granuloma.

Authors:  C Agostini; U Basso; G Semenzato
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

10.  Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients.

Authors:  G Semenzato; C Agostini; L Trentin; R Zambello; M Chilosi; A Cipriani; E Ossi; M R Angi; L Morittu; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.